LGC accelerates the development of new medicines with extractables and leachables services

News (ZH) - LGC is helping customers to identify and quantify the compounds present in those components in direct contact with a drug product or patient

LGC launches new service for stability testing

News (ZH) - This new service enables continuous recording and monitoring of essential data on the impact of environmental factors, such as temperature and humidity, on the quality of a pharmaceutical product

LGC launches cGMP cell-based assay capability

News (ZH) - The cGMP service is an extension to the existing cell-based assay capability that LGC’s experienced team offer for biopharmaceutical development

LGC becomes first bioanalytical Contract Research Organisation to offer HD-X platform in a regulated environment

News (ZH) - The HD-X has been unveiled at LGC’s GLP/GCP-accredited lab in Fordham

OliX Pharmaceuticals signs agreement with LGC to accelerate production of asymmetric siRNA for the treatment of Sub-Retinal Fibrosis and Wet Macular Degeneration

News (ZH) - LGC will produce active pharmaceutical ingredients for preclinical and clinical study of OLX301D programme

LGC and Q2 Solutions announce global bioanalytical strategic partnership

News (ZH) - Will each contribute extensive experience and capabilities in small and large molecule bioanalysis to support customer-centric approach

Ampersand-backed Alliance Pharma to acquire LGC’s Drug Development Solutions Business (“DDS”) and welcomes KKR as joint shareholder

News (ZH) - DDS is a European provider of Bioanalytical and Analytical and Materials Science Solutions to pharma, biopharma, consumer healthcare and consumer products clients, located in Cambridge and Sandwich, UK